Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice

Publisher： Karger

E-ISSN： 1423-0097|126|1|68-77

ISSN： 1018-2438

Source： International Archives of Allergy and Immunology, Vol.126, Iss.1, 2001-10, pp. : 68-77

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 218-219

Karger

Access to resources Recommend Favorite

Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1

By  

International Archives of Allergy and Immunology, Vol. 138, Iss. 1, 2005-09 ,pp. : 59-66

Karger

Access to resources Recommend Favorite

Expression of a Human IgG4 Antibody, BAB2, with Specificity for the Major Birch Pollen Allergen, Bet v 1 in Escherichia coli: Recombinant BAB2 Fabs Enhance the Allergic Reaction

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 190-192

Karger

Access to resources Recommend Favorite

A Model System to Study the Environment-Dependent Expression of the Bet v 1a Gene Encoding the Major Birch Pollen Allergen

By  

International Archives of Allergy and Immunology, Vol. 134, Iss. 1, 2004-05 ,pp. : 1-9

Karger

Access to resources Recommend Favorite

IgE Mimotopes of Birch Pollen Allergen Bet v 1 Induce Blocking IgG in Mice

By  

International Archives of Allergy and Immunology, Vol. 124, Iss. 1-3, 2012-01 ,pp. : 395-397

Karger

Access to resources Recommend Favorite